copd
DESCRIPTION
COPD. Review. Progressive Syndrome Expiratory airflow obstruction Chronic airway and lung parenchyma inflammation. Preventable, treatable 24 million adults in US 4th leading cause of death in US: Heart disease Cancer Stroke COPD Accidents Diabetes. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/1.jpg)
COPD
Review
![Page 2: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/2.jpg)
![Page 3: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/3.jpg)
• Progressive• Syndrome• Expiratory airflow obstruction• Chronic airway and lung parenchyma
inflammation
![Page 4: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/4.jpg)
![Page 5: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/5.jpg)
• Preventable, treatable• 24 million adults in US• 4th leading cause of death in US:
– Heart disease– Cancer– Stroke – COPD– Accidents– Diabetes
![Page 6: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/6.jpg)
• GOLD: global initiative for chronic obstructive lung diseasae– Expiratory airflow not fully reversible– Progressive, association with an “abnormal”
lung response to noxious gases and particles
![Page 7: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/7.jpg)
• Two major clinical types– Chronic bronchitis: inflammation of small and
medium sized airways– Leads to expiratory defect, chronic cough,
sputum production and dyspnea
![Page 8: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/8.jpg)
• Emphysema– Inflammation of lung parenchyma– Loss of elastic recoil of lungs– Airflow limitation– Hypoxemia– dyspnea
![Page 9: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/9.jpg)
![Page 10: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/10.jpg)
![Page 11: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/11.jpg)
![Page 12: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/12.jpg)
![Page 13: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/13.jpg)
COPD
• Irreversible airflow (as measured by FEV1 or FEV1/FVC) caused by:– Increased airway resistance in the conducting
airways, or,– Increased lung compliance due to destruction
of lung parenchyma/elasticity• Or a combination of both the above
![Page 14: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/14.jpg)
Chronic Bronchitis
• Inflammation of the central airways (airways >4mm diameter and peripheral airways < 2 mm)
• Extends to gland ducts and into the mucus producing glands– This produces increase mucus– Defective mucociliary clearance– Disruption (destruction) of epithelial barrier
![Page 15: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/15.jpg)
• Airflow obstruction occurs primarily in the small airways which are <2mm diameter
![Page 16: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/16.jpg)
Emphysema
• Decrease in elastic recoil force needed to drive air out of lung (“paper sack”)
• Centrilobular or centriacinar form is associated with cigarette smoking– Major destruction of the acinus at the
respiratory bronchiole level
![Page 17: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/17.jpg)
• Panlobular or panacinar form is associated with alpha-1 antitrypsin disease– Destruction of the entire acinus– Occurs as a result of an imbalance of
proteolytic enzymes in lung tissue
![Page 18: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/18.jpg)
• In both forms of the disease, the cause of COPD is inflammation, both in the airways and in lung tissue
![Page 19: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/19.jpg)
Inflammation
• Smoking, in• Chronic Bronchitis
– Neutrophils and macrophages, lymphocytes• Emphysema
– Cellular changes in terminal bronchioles– Destruction (protease enzymes) extracellular
matrix of aleveoli– Ineffective repair mechanism
![Page 20: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/20.jpg)
COPD vs Asthma
• Asthma– Anatomical location of inflammation– With bronchodilators and steroids, lung
function returns to normal or near-normal with occasional transient inflammation
• COPD– Anatomical (airways and lung parenchyma)– Some degree of irreversible deterioration
![Page 21: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/21.jpg)
• Cellular differences• Asthma
– Eosinophils– Mast cells– Lymphocytes– CD4 T cells
![Page 22: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/22.jpg)
Same cells: CB & Emphysema
• COPD– Neturophils– Macrophages– No mast cells– CD8 T cells
![Page 23: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/23.jpg)
COPD Asthma
Age 5th decade All agesSmoking Hx >10 pack years None, minimalSputum CB frequent Frequent, clearAllergies Infrequent FrequentCourse of disease
Progressive worsening
Nonprogressive
Symptoms Persistent Intermittent
![Page 24: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/24.jpg)
A 20 pack year smoking history indicates that the subject’s lungs have received 20 of these short cyclic exposures per day for a cumulative total of 7300 exposures per year and 146,000 exposures over the lifetime of their smoking habit.
![Page 25: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/25.jpg)
GOLD StagesCOPD Stage Airflow Limitation
1 Mild FEV1/FVC <70% FEV1 >80% predicted
2 Moderate FEV1/FVC <70% FEV1 <50%- <80%
3 Severe FEV1/FVC <70% FEV1 <30% - <50%
4 Very severe FEV1/FVC <70% FEV1 <30% or FEV1 <50% with chronic respiratory failure
![Page 26: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/26.jpg)
![Page 27: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/27.jpg)
In Sum
Toxic gases and particles generated in tobacco smoke come into contact with lung tissues each time a puff of smoke is inhaled
Tissue injury recurs in a cyclic fashion as each cigarette is smoked
![Page 28: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/28.jpg)
Chronic Bronchitis
Inflammation:mucociliary clearance disruptedepithelial barrier/defense lostincreased sputum production (goblet cells)irreversible airway remodelingairflow obstruction
![Page 29: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/29.jpg)
Emphysema
In lung tissue, the chronic inhalation also causes inflammation, destroys elastic recoil, disrupts balance of protective, anti-protease enzymes
proteinase-antiproteniase theoryelastase-antielastase
“extracellular matrix”
![Page 30: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/30.jpg)
Toxins/free radicals Cigarette smoke Toxins/free radicals
Stimulation of alveolar macrophages &other inflammatory cells
chemotactic factors
Airway inflammation Lung (pulmonary) inflammation&
Injury to parenchymal cells
Airflow obstruction Proteinase inhibitors (alpha1-antitrypsin)
Injury to extracellular matrix
Repair of extracellular matrix
Chronic Bronchitis Emphysema
Cough excessive sputum production dyspnea at rest
![Page 31: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/31.jpg)
![Page 32: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/32.jpg)
Alpha1-antitrypsin
• Neutrophil elastase linked to alpha-1 antitrypsin deficiency
• Other cells producing proteinase enzymes: macrophages, lymphocytes—still not determined
![Page 33: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/33.jpg)
![Page 34: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/34.jpg)
![Page 35: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/35.jpg)
![Page 36: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/36.jpg)
![Page 37: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/37.jpg)
![Page 38: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/38.jpg)
![Page 39: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/39.jpg)
![Page 40: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/40.jpg)
![Page 41: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/41.jpg)
![Page 42: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/42.jpg)
![Page 43: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/43.jpg)
![Page 44: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/44.jpg)
• Decreased airflow resistance (airways) and decreased elastic recoil lead to:
• Hyperinflation• V/Q mismatching, which further leads to
decreases in Pa02, increases in PaC02 with decreased ventilation
![Page 45: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/45.jpg)
• In end-stage COPD– Cor pulmonale– Pulmonary vasoconstriction (in presence of
chronic low Pa02)– Increased pulmonary vascular resistance– Increased pressure, leading eventually to right
heart enlargement
![Page 46: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/46.jpg)
CXR
![Page 47: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/47.jpg)
COR Pulmonale
![Page 48: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/48.jpg)
![Page 49: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/49.jpg)
![Page 50: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/50.jpg)
![Page 51: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/51.jpg)
Emphysema
![Page 52: COPD](https://reader034.vdocument.in/reader034/viewer/2022051821/56815dea550346895dcc11fe/html5/thumbnails/52.jpg)